Skip to content

Cumberland Pharmaceuticals Inc.: 10-K filed 2025-03-07

What Cumberland Pharmaceuticals Inc. reported in its annual report filed 2025-03-07 (fiscal FY 2024): 51 published measures, 144 facts as tagged in accession 0001628280-25-011366.

This filing

Form
10-K (annual report)
Filed
2025-03-07
Fiscal period
fiscal FY 2024
Accession
0001628280-25-011366 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-3175,583,410USD
At 2023-12-3181,776,075USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-12-3153,037,433USD
At 2023-12-3152,516,206USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-3122,853,494USD
At 2023-12-3129,603,441USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-12-3117,964,184USD
At 2023-12-3118,321,624USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1,903,814USD92
2024-01-01 to 2024-12-31-6,479,770USD366
2024-07-01 to 2024-09-30-1,544,081USD92
2024-04-01 to 2024-06-30-1,085,612USD91
2024-01-01 to 2024-03-31-1,946,263USD91
2023-10-01 to 2023-12-31-6,294,406USD92
2023-01-01 to 2023-12-31-6,279,320USD365
2023-07-01 to 2023-09-30-1,049,298USD92
2023-04-01 to 2023-06-30872,200USD91
2023-01-01 to 2023-03-31192,184USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-612,186USD366
2023-01-01 to 2023-12-316,093,821USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-12-3166,461USD366
2023-01-01 to 2023-12-31281,268USD365

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-10-01 to 2024-12-3110,435,569USD92
2024-01-01 to 2024-12-3137,867,945USD366
2024-07-01 to 2024-09-309,085,826USD92
2024-04-01 to 2024-06-309,848,849USD91
2024-01-01 to 2024-03-318,497,701USD91
2023-10-01 to 2023-12-319,353,066USD92
2023-01-01 to 2023-12-3139,552,507USD365
2023-07-01 to 2023-09-3010,085,926USD92
2023-04-01 to 2023-06-3010,888,877USD91
2023-01-01 to 2023-03-319,224,638USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-12-31196,904USD366
2023-01-01 to 2023-12-31-7,424,472USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-12-3157,842USD366
2023-01-01 to 2023-12-31-105,695USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-23,967,931USD
At 2023-12-31-17,488,161USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-12-3114,060,272shares366
2023-01-01 to 2023-12-3114,298,774shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-12-3114,060,272shares366
2023-01-01 to 2023-12-3114,298,774shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-0.14USD/shares92
2024-01-01 to 2024-12-31-0.46USD/shares366
2024-07-01 to 2024-09-30-0.11USD/shares92
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-03-31-0.14USD/shares91
2023-01-01 to 2023-12-31-0.44USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-0.14USD/shares92
2024-01-01 to 2024-12-31-0.46USD/shares366
2024-07-01 to 2024-09-30-0.11USD/shares92
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-03-31-0.14USD/shares91
2023-01-01 to 2023-12-31-0.44USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-22,669USD366
2023-01-01 to 2023-12-3145,769USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-12-31277,365USD
At 2023-12-31367,903USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-12-31301,895USD366
2023-01-01 to 2023-12-31365,040USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1,842,039USD92
2024-01-01 to 2024-12-31-6,432,409USD366
2024-07-01 to 2024-09-30-1,694,432USD92
2024-04-01 to 2024-06-30-1,026,688USD91
2024-01-01 to 2024-03-31-1,869,250USD91
2023-10-01 to 2023-12-31-6,179,239USD92
2023-01-01 to 2023-12-31-9,554,661USD365
2023-07-01 to 2023-09-30-1,866,603USD92
2023-04-01 to 2023-06-3022,859USD91
2023-01-01 to 2023-03-31-1,531,678USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-12-3136,452,158USD
At 2023-12-3135,714,410USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-01-01 to 2024-12-31605,508USD366
2023-01-01 to 2023-12-31667,861USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-3131,621,729USD
At 2023-12-3127,982,249USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-12-3113,914,266USD
At 2023-12-3114,037,629USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2024-12-31914,000USD
At 2023-12-31914,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-12-3117,973,449USD
At 2023-12-3122,607,918USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-12-3111,701,466USD
At 2023-12-319,758,176USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2024-01-01 to 2024-12-31579,049USD366
2023-01-01 to 2023-12-31740,533USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-12-313,999,995USD
At 2023-12-314,609,362USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-12-314,816,206USD366
2023-01-01 to 2023-12-315,834,229USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-3113,952,624shares
At 2023-12-3114,121,833shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-12-3117,964,184USD
At 2023-12-3118,321,624USD
At 2022-12-3119,757,970USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2024-12-3122,545,977USD
At 2023-12-3129,259,869USD
At 2022-12-3135,974,006USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-316,176,923USD
At 2023-12-316,674,394USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-12-315,296,247USD
At 2023-12-315,644,339USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-12-312,669,208USD
At 2023-12-312,605,976USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-12-312,391,843USD
At 2023-12-312,238,073USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-312,784,016USD
At 2023-12-312,692,921USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-316,299,795USD
At 2023-12-316,453,566USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-12-3112,250,955USD
At 2023-12-3113,596,528USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-12-312,786,513USD
At 2023-12-313,025,248USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2024-12-31207,059USD
At 2023-12-31220,402USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-6,466,384USD366
2023-01-01 to 2023-12-31-6,284,997USD365

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1,901,637USD92
2024-01-01 to 2024-12-31-6,443,715USD366
2024-07-01 to 2024-09-30-1,536,969USD92
2024-04-01 to 2024-06-30-1,102,637USD91
2024-01-01 to 2024-03-31-1,902,472USD91
2023-10-01 to 2023-12-31-6,301,987USD92
2023-01-01 to 2023-12-31-6,330,766USD365
2023-07-01 to 2023-09-30-1,063,219USD92
2023-04-01 to 2023-06-30862,154USD91
2023-01-01 to 2023-03-31172,286USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-12-3111,126,901USD366
2023-01-01 to 2023-12-3110,651,915USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-01-01 to 2024-12-314,902,560USD366
2023-01-01 to 2023-12-314,935,954USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-01-01 to 2024-12-314,748,252USD366
2023-01-01 to 2023-12-318,102,648USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-22,669USD366
2023-01-01 to 2023-12-3145,769USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-12-31569,230USD366
2023-01-01 to 2023-12-31647,137USD365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-01-01 to 2024-12-3115,000USD366
2023-01-01 to 2023-12-31108,823USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,943,290USD366
2023-01-01 to 2023-12-31-3,404,949USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-2,408,397USD366
2023-01-01 to 2023-12-3123,143USD365

Inspect the source

Entity
Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured
2026-09-20T05:21:29.619Z
SEC response SHA-256
b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))